Table 1.

Baseline characteristics of the overall population and a subgroup of patients with UACR≥30 mg/g

CharacteristicOverall PopulationUACR≥30 mg/g Subgroup
Glimepiride (n=482)CanagliflozinGlimepiride (n=76)Canagliflozin
100 mg (n=483)300 mg (n=485)100 mg (n=76)300 mg (n=78)
Age, yr56.3 (9.0)56.4 (9.5)55.8 (9.2)58.5 (8.0)55.6 (10.2)55.8 (9.6)
Female, n (%)219 (45.4)231 (47.8)244 (50.3)28 (36.8)30 (39.5)36 (46.2)
HbA1c, %7.8 (0.8)7.8 (0.8)7.8 (0.8)7.9 (0.8)7.9 (0.9)8.0 (0.8)
Diabetes duration, yr6.6 (5.0)6.5 (5.5)6.7 (5.5)6.9 (4.9)7.7 (6.6)8.2 (6.4)
SBP, mmHg129.5 (13.52)130.0 (12.40)129.9 (13.72)136.7 (12.52)133.7 (11.79)133.0 (15.32)
DBP, mmHg78.9 (8.40)78.8 (7.98)79.1 (8.34)81.7 (9.05)80.6 (8.98)80.9 (8.42)
eGFR, ml/min per 1.73 m289.5 (17.5)89.7 (19.3)91.4 (19.4)86.5 (18.5)91.0 (23.9)91.1 (23.9)
UACR, mg/ga8.2 (5.75; 17.98)8.7 (5.74; 17.52)8.6 (5.28; 20.64)60.1 (41.29; 124.91)56.5 (40.17; 115.49)75.2 (43.35; 173.11)
ACEI/ARB use, n (%)303 (62.9)287 (59.4)291 (60.0)49 (64.5)44 (57.9)45 (57.7)
  • Data are mean (SD) unless otherwise indicated. eGFR data at baseline were missing in seven patients in the glimepiride group, six patients in the canagliflozin 100 mg group, and eight patients in the canagliflozin 300 mg group. SBP, systolic BP; DBP, diastolic BP; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

  • a 25th and 75th percentile reported.